Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New S...(e novel scientific leads workingtogether...),Health

Date:10/11/2007

e novel scientific leads, working together in new ways," said Dr. Jos Esparza, senior advisor on HIV vaccines for the Bill & Melinda Gates Foundation. "The Gates Foundation is committed to supporting the Enterprise secretariat, and to helping advance priorities in the Enterprise scientific plan through our support of the Collaboration for AIDS Vaccine Discovery."

Dr. Bernstein received his Ph.D. in Medical Biophysics at the University of Toronto. Following postdoctoral work in London where he first began working on retroviruses, he returned to Canada to join the faculty of the Ontario Cancer Institute. He later served as head of the Division of Molecular and Developmental Biology at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital, and then its director of research.

An internationally renowned researcher, he has made extensive contributions to the study of embryonic development, hematopoiesis and cancer. Dr. Bernstein has received a number of national and international awards for his research, and has served on a large number of international scientific bodies, including the scientific board of the Grand Challenges in Global Health initiative.

"HIV affects more than 40 million people worldwide, and nearly 5 million people are newly infected every year," said Dr. Helene Gayle, President and CEO of CARE and chair of the Enterprise coordinating committee. "An HIV vaccine, once developed, has the potential to save millions of lives and stop this pandemic. The Enterprise can speed the day when AIDS will no longer threaten us or our children."

About the Global HIV Vaccine Enterprise:

The Global HIV Vaccine Enterprise is an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine by implementing a shared scientific plan, mobilizing significant new funding for vaccine research, and promoting more efficient, faster ways for researchers to share successes and failu
'/>"/>

SOURCE The Global HIV Vaccine Enterprise Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Global Rabies Treatment May be Possible with NanoViricides Drugs
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
7. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
8. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
9. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma